Corvus Pharmaceuticals, Inc. (CRVS) vs Pacific Biosciences of California, Inc. (PACB)
A side-by-side comparison of Corvus Pharmaceuticals, Inc. and Pacific Biosciences of California, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CRVS
Corvus Pharmaceuticals, Inc.
$10.56HealthcareDelayed quote: Oct 6, 2026, 12:05 PM EDT
PACB
Pacific Biosciences of California, Inc.
$2.67HealthcareDelayed quote: Oct 6, 2026, 12:00 PM EDT
Total return — CRVS vs PACB
growth of $100 · dividends reinvested · last 10yCRVS -34.5% (-4.1%/yr)PACB -68.1% (-10.8%/yr)CRVS compounded faster over this window
CRVS PACB
CRVS vs PACB: by the numbers
- •CRVS is the larger company ($888M vs $828M market cap).
- •Both run net losses; CRVS's is the smaller (0.00% vs -82.49% net margin).
Metrics side by side
Valuation
| Metric | CRVS | PACB |
|---|---|---|
| P/S ratio | N/A | 5.20 |
| P/B ratio | 3.94 | N/A |
Profitability
| Metric | CRVS | PACB |
|---|---|---|
| Gross margin | 0.00% | 35.97% |
| Operating margin | 0.00% | -348.46% |
| Net margin | 0.00% | -82.49% |
| ROE | -24.02% | N/A |
| ROIC | -25.25% | -23.80% |
Growth (annualized)
| Metric | CRVS | PACB |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 8.52% |
| Total return CAGR (5Y) | 17.88% | -35.20% |
Frequently asked
- How have CRVS and PACB total returns compared?
- Over the past 10 years, CRVS delivered -4.26% and PACB delivered -10.80% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Corvus Pharmaceuticals ROEPacific Biosciences of California ROECorvus Pharmaceuticals operating marginPacific Biosciences of California operating marginCorvus Pharmaceuticals revenue growthPacific Biosciences of California revenue growthCorvus Pharmaceuticals free cash flowPacific Biosciences of California free cash flow
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.